Experience with a failed postmarketing drug surveillance program.
作者信息
Hollister L E, Overall J E
出版信息
J Clin Pharmacol. 1984 Jan;24(1):3-5. doi: 10.1002/j.1552-4604.1984.tb01807.x.
Abstract
摘要
相似文献
1
Experience with a failed postmarketing drug surveillance program.
J Clin Pharmacol. 1984 Jan;24(1):3-5. doi: 10.1002/j.1552-4604.1984.tb01807.x.
2
Post-marketing surveillance or drug acceptability study?上市后监测还是药物可接受性研究？
Br J Clin Pharmacol. 1987 Sep;24(3):281-2. doi: 10.1111/j.1365-2125.1987.tb03170.x.
3
Postmarketing surveillance of adverse drug reactions: problems and solutions.药品不良反应的上市后监测：问题与解决方案
CMAJ. 1986 Jul 1;135(1):27-32.
4
Post-marketing surveillance in the UK (1984).英国的上市后监测（1984年）。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
5
Techniques of postmarketing surveillance. An overview.上市后监测技术。概述。
Med Toxicol. 1986 Jul-Aug;1(4):237-46. doi: 10.1007/BF03259840.
6
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
7
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Apr 14;288(6424):1155-6. doi: 10.1136/bmj.288.6424.1155.
8
Immortality for old drugs?
Lancet. 1984 Jun 30;1(8392):1460-1. doi: 10.1016/s0140-6736(84)91946-9.
9
Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.改进美国食品药品监督管理局确保药品上市后安全的授权。
JAMA. 2011 Oct 12;306(14):1595-6. doi: 10.1001/jama.2011.1457.
10
Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.药物不良反应的发现。选定的IV期研究与自发报告方法的比较。
JAMA. 1983;249(16):2226-28. doi: 10.1001/jama.249.16.2226.
引用本文的文献
1
Development of new drugs in man: a review.人体新药研发综述
J R Soc Med. 1986 Feb;79(2):96-9. doi: 10.1177/014107688607900210.
Zotero 插件